Metadon Abcur

Methadone Hydrochloride, the active ingredient in Metadon Abcur, is an opioid agonist presented as an oral dosage form for oral use. It is indicated for opioid substitution therapy and for the relief of moderate to severe chronic pain when other analgesics are insufficient, helping to manage opioid dependence and provide analgesia in adult patients.

GNH USA supplies Metadon Abcur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets.

Methadone Hydrochloride is used in the management of opioid dependence and chronic pain, acting on the central opioid system. - Opioid dependence: reduces withdrawal symptoms and cravings, supporting maintenance therapy. - Chronic pain: provides long‑acting analgesia for moderate to severe pain when other agents are inadequate. - Palliative care: alleviates severe pain in end‑of‑life settings where additional opioid support is required.

Methadone Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Constipation - Dizziness - Sweating - Insomnia - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe hypotension - Seizures - Anaphylactic reactions - Adrenal insufficiency

When prescribing Metadon Abcur, clinicians should consider several safety measures. - Assess cardiac function: obtain a baseline ECG due to risk of QT prolongation. - Monitor for respiratory depression: especially during initiation or dose changes. - Avoid use in patients with severe hepatic impairment: dose adjustment may be required. - Educate patients on signs of overdose and safe storage. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methadone Hydrochloride interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concomitant use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase methadone plasma levels, risking toxicity. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics) may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce methadone concentrations, leading to withdrawal. - Drugs affecting electrolyte balance (e.g., diuretics) can increase risk of arrhythmia. - Alcohol use may potentiate sedative effects.